Neurotech International Ltd. · ASX:NTI
Neurotech International — Investor Presentation (July 2024)
20 slides from Neurotech International's investor presentation, Jul 10, 2024
Slide 1: Improving Lives Investor Presentation
For personal use only Improving Lives Investor Presentation Dr Tom Duthy Executive Director 10 July 2024
Slide 2: Disclaimer
Disclaimer IMPORTANT INFORMATION Purpose of presentation: This presentation (including this document, any related video or oral These events are, as at the date of this presentation, expected to take place, but there cannot be any guarantee that such will occur as anticipated, or at all, given that
Slide 3: A short video on Neurotech
A short video on Neurotech For personal use only 3
Slide 4: Corporate / Capital Summary
Corporate / Capital Summary $0.074 $75.2M $13.6M ~2,450 For personal use only Share price (as at 8 Jul 2024) Market Pro-Forma Cash No. of shareholders capitalisation 31 March ’24* 1016.7M 176.5M $6.5M 45.4% Share on issue Options^ FY23 R&D Exp. Top 20 Holders (up from $2.6M in FY22) • 31 March cash
Slide 5: Neurotech Four Core Strategies
Neurotech Four Core Strategies For personal use only Focus On Rare Focus on Paediatric Patients Neurological Disorders with Neuroinflammation Focus on Partnering with Focus On Drug Product Key Opinion Leaders / Development Clinicians 5
Slide 6: Therapeutic Agent: NTI164
Therapeutic Agent: NTI164 THC < 0.3% For personal use only Convenient 1x or 2x (split dose) High potency, Broad Spectrum Cannabinoid Formulation in Oil, C. Major constituent Cannabidiolic oral formulation in oil, ideal acid (CBDA) format for pediatric patients sativa L. (Plant Derived) 20mg/kg (CBDA
Slide 7: Intellectual Property – 2024
Intellectual Property – 2024 Other IP & Barriers to Entry Vertically Integrated: Seed to Patient Controlled (Trade Secret: continuity of production to SOP, extraction(s)) For personal use only Orphan Drug Designation(s) 10 Years Market Exclusivity from Approval – Europe 7 Years Market Exclusivity fr
Slide 8: Clinical Pipeline – 2024
Clinical Pipeline – 2024 Pre-Clinical Phase I/II Phase II/III For personal use only Other Licensed NTI164 NTI164 Strains Cerebral Palsy ASD Synthetic Cannabinoid(s) NTI164 combinations PANDAS / PANS1 NTI164 ASD2 World-first clinical trials, and first (90 week+ open label extension) time substantial
Slide 9: Our Target Markets
Our Target Markets Lack of effective therapies, significant unmet medical need Annual Drug Therapy Market opportunity US$2 billion* US$2 billion US$1.4 billion1 US$4.3 billion For personal use only Orphan Orphan Autism Spectrum Disorder (ASD) Rett Syndrome PANDAS/PANS Cerebral Palsy (CP) • Prevalenc
Slide 10: CBD OTC Market - Australia
CBD OTC Market - Australia Highly Competitive, Low Margin, Low Price, Lack of Differentiation, Stringent Regulatory Oversight – Not the Market for NTI164 For personal use only 48 44/35 0 Number of over-the-counter (OTC) Domestic Manufacturers / Importers CBD Products Registered on the CBD products a
Slide 11: Why a Prescription Medicine Pathway for NTI164?
Why a Prescription Medicine Pathway for NTI164? Epidiolex® : The only FDA, TGA, EMA approved high potency CBD-only oil (Schedule 4) Approved to manage seizures in 3 orphan ‘rare’ neuro disorders In….Dravet Syndrome, Lennox-Gaustat Syndrome and Tuberous Sclerosis Complex For personal use only What do
Slide 12: NTI164 – Ideal Target Product Profile
NTI164 – Ideal Target Product Profile Prescription Only Medicine For personal use only FDA, EMA, TGA Approved Multiple Paediatric Neurological Disorders Premium Pricing Reflecting Clinical Investment Reimbursed Orphan Designations + Other Regulatory Levers 1. Based on 73m children with 1/15,700 livi
Slide 13: Epidiolex – Actual Target Product Profile
® Epidiolex – Actual Target Product Profile Prescription Only Medicine For personal use only FDA, EMA, TGA Approved Multiple Paediatric Neurological Disorders Premium Pricing Reflecting Clinical Investment Reimbursed NTI164……not re-inventing the wheel, simply aligning to a proven model Orphan Design
Slide 14: Autism │ Rett │ PANDAS/PANS
Autism │ Rett │ PANDAS/PANS “The goals of treatment for Autism are to improve core deficits in social communication and social interactions and minimize the impact of restricted behaviours, with an overarching goal to help children develop greater functional skills and independence.” 1 “Caregivers o
Slide 15: No Safety concerns – across all trials to date
No Safety concerns – across all trials to date 94 children across all trials (inc. extensions reported to date, max 2 years) Autism │ Rett │ PANDAS/PANS Normal Minor Adverse Events For personal use only Kidney/Liver Function Mild Nausea/vomiting ~5-15% Vital Signs No diarrhoea Blood Chemistry No wei
Slide 16: NTI164 Efficacy is Strong and Durable
NT1164 Efficacy is Strong and Durable Autism Rett PANDAS/PANS 56% Improvement in Severity of illness at 12 weeks 30% Improvement in RSBQ, 205% from 4-12 weeks 38% Improvement in Disease Severity at 52 weeks For personal use only 46% Patients Much Improved / Improved at 8 weeks 60% Improvement in pat
Slide 17: Recent Clinician Developments
Recent Clinician Developments A/Prof Carolyn Ellaway Appointed Chief Medical Officer (CMO) • Internationally recognised clinical geneticist and was the lead Investigator on the Company’s successful Phase I/II Rett Syndrome clinical trial • Key opinion leader engagement along with overseeing the deve
Slide 18: Key Milestones – NTI164
Key Milestones – NTI164 1H CY2024 2H CY2024 • HREC/TGA Approval Cerebral Palsy Phase I/II Clinical Trial • Appointment of A/Prof Carolyn Ellaway as CMO For personal use only • 24-week PANDAS/PANS Phase I/II Clinical Trial Data • Filing of Orphan Drug Designation USA – PANDAS/PANS • Rett Syndrome Pha
Slide 19: Outlook
Outlook • Completed $10.0 million capital raise in April, $13.6 million in available pro-forma funds: well-funded to accelerate development activities in Australia and US, EU • Continued safety/efficacy data releases across 3 indications (ASD, PANDAS/PANS, Rett) as For personal use only patients ent
Slide 20: Contact Details
For personal use only Contact Details Dr Tom Duthy Executive Director [email protected] +61 402 493 727 *This presentation has been authorised by the Board of Neurotech International Limited www.neurotechinternational.com Neurotech International Limited (ASX: NTI) 20
Neurotech International — Investor Presentation (July 2024) on 6ix